The Dish’s Weekly Biotechnology News Wrap Up – June 7, 2019

This week’s headlines include: In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful, US aims to help more cancer patients try experimental drugs, Bluebird bags EU conditional marketing authorisation for Zynteglo, Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study, and The Health 202: The Supreme Court banned patenting genes. But Congress might change that.

Podcasts:

Check out our podcast channel. We have over 30 great podcasts covering drug discovery, stem cell culture, upstream and downstream biomanufacturing and more! Click below to download from iTunes or Google play:
Available on Google PlayAvailable on itunes

 


In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:

cell-culture-dish-logo

Novel Acoustic Platform Provides Gentler, More Efficient Solution for Cell Processing

Cell and gene therapies are in need of evolving manufacturing technologies to move products from research, through development and into, commercial manufacturing. As more cell and gene therapy products achieve clinical success, more investments are being made in creating manufacturing technologies to support the industry. There are several advancements in this area including the closing and automating of many manufacturing processes and increasing efficiencies with the creation of fit for purpose equipment and consumables. There are still, however, many needed improvements to further increase productivity and reduce cost…

Rapid Mycoplasma Testing for Biomanufacturing Applications

Increasingly the quality of raw materials used in cell culture media and supplements is being closely examined for any potential negative impact on cell culture or the final product quality. One area of concern is biomanufacturing contamination. While there are certainly many possible entry points for cell culture contamination, contaminated raw materials is high on the list. Of the possible contaminants, mycoplasma is often a big concern because it is fairly resilient in laboratory environments, resistant to most, if not all antibiotics, and also contamination in culture is not always obvious. Yet, mycoplasma contamination can have a devastating impact on biopharmaceutical development and production. As a result, having adequate mycoplasma monitoring in place is critical for minimizing the risk and ultimately impact of contamination…

Optimizing Fed Batch Culture – Developing New Tools and Methods to Improve Production

The past decade has seen a surge in the development of gene therapies. Currently there are over 1,000 cell and gene therapy clinical trials underway worldwide.1 While the majority of current trials are still in Phase I or Phase II, there are more than 90 trials in Phase III. In fact, at last year’s BIO International Convention, Scott Gottlieb, Commissioner of the US Food and Drug Administration (FDA) stated that he expects the FDA to approve 40 gene therapies by 2022.2

Transfection Reagent Portfolio Enables Seamless Scalability from R&D to Commercial Therapeutic Viral Vector Manufacturing

One common challenge in viral vector production is transitioning from research-based production to more rigorous quality and safety profiles for clinical and commercial manufacture. In fact, raw materials used in production at research scale are often not cGMP-compliant and therefore fit for clinical or commercial manufacturing. This means that critical raw materials frequently need to be replaced with cGMP grade material sourced from approved suppliers during process scale up. cGMP grade materials are manufactured under strict conditions and must pass rigorous testing. This higher manufacturing standard reduces the risk of introducing adventitious agents into clinical and commercial viral vector manufacturing…

Spheroid Cell Culture – Practical solutions for frequently asked questions

The past decade has seen an increase in publications recognizing the value of culturing cells in three dimensions (3D) and the use of these 3D cell culture models has shown utility in many areas of research from cancer biology to regenerative medicine. One of the most common 3D cell culture types is spheroids. Spheroids more accurately recapitulate the native in vivo microenvironment with respect to cellular function and response to drugs than more traditional two-dimensional (2D) models. That said, working with spheroids is not without its challenges. Many labs working with spheroids have run into technical hurdles incorporating them into existing cell culture workflows. Whether it is issues with handling or optimizing protocols to assaying cells in 3D, these obstacles can be overcome…


The Down Stream Column

Bioburden Control Strategies for Continuous Downstream Processing

Implementing continuous bioprocessing for biomanufacturing has been increasing in interest. As a result, questions have arisen about the implementation of this strategy for downstream processes. Of particular interest is maintaining a high degree of bioburden control in continuous downstream process. While bioburden control strategies for continuous processing focus on prevention, not unlike batch processing, many want to know if there are specific strategies that should be implemented with continuous bioprocessing that are different than those used in batch processing…

Cool Tool – Innovative sorbents enable a robust and streamlined protein purification process

Monoclonal antibodies have long been purified using a platform approach. This platform mainly consists of three chromatography steps. These include a Protein A based affinity chromatography step followed by polishing steps. The purpose of the affinity chromatography is to capture the mAb, while the polishing steps remove any remaining impurities, such as residual DNA, host cell proteins, viruses and aggregates. There are options in the selected polishing steps, but often they involve cation exchange or hydrophobic interaction. Increasingly membrane chromatography is being used as a polishing step to remove any remaining contaminants…

Optimizing mAb Purification with Highly Selective Mixed-mode Cation Exchange Sorbent

In today’s market, mAbs are produced for several therapeutic applications, yet they are not a homogeneous family of products. Each mAb is unique, based on its isoelectric point, hydrophobicity and ability to aggregate; the contaminant HCP content is also process-dependent. As drug manufacturers seek to produce mAbs for various application, they are also looking to streamline processes for efficiency and quality…

Scalable Protein A Chromatography for High-Throughput Process Development

Process development is a critical part of biomanufacturing, but it can be very time and resource intensive. With recent industry initiatives around speed to market, process development is an area that could really benefit from high throughput solutions. One high-throughput process development tool for chromatography is the use of 96-well plates. These plate platforms permit automated screening of large numbers of conditions very efficiently and use only a small amount of material for testing. This platform is great for screening but requires bridging experiments to translate results to process scale. In addition, automating the 96-well process requires investment in liquid handling equipment in order to reach the full potential of the platform…

Utilizing High-Throughput Process Development Tools to Create a Purification Process for a Biosimilar Molecule

Biosimilar molecules have some unique manufacturing requirements that must be taken into account when planning process development. The requirements for process development typically require a good deal of selectivity, cost-efficiency and the need to meet aggressive timelines. These lend themselves to a process development approach that incorporates high throughput…


Headlines:

“In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful,” FierceBiotech

“The $74 billion deal that will see Bristol-Myers Squibb subsume Celgene into its ranks is all but done, but it’s been a rocky path. Today, Celgene delivered some positive optics for its would-be parent…”

 

“US aims to help more cancer patients try experimental drugs,” The Associated Press

“Sally Atwater’s doctor spent two months on calls, messages and paperwork to get her an experimental drug he thinks can fight the lung cancer that has spread to her brain and spine. Nancy Goodman begged eight companies to let her young son try experimental medicines for a brain tumor that ultimately killed him, and “only three of the companies even gave me a reason why they declined,” she said…”

“Bluebird bags EU conditional marketing authorisation for Zynteglo,” PharmaTimes

“Bluebird bio has announced that its gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) has been granted conditional marketing authorisation in Europe for certain patients 12 years and older with transfusion-dependent β-thalassaemia (TDT)…”

“Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study,” Reuters

“An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday…”

“The Health 202: The Supreme Court banned patenting genes. But Congress might change that.” The Washington Post

“The Supreme Court has ruled unanimously that genes can’t be patented. But a bipartisan group of lawmakers is trying to change that with legislation pushed by biopharmaceutical companies and patent lawyers…”